

DiaMedica

06:49 03 May 2018

OTCMarkets UPDATE: DiaMedica Therapeutics, Choom Holdings and more

The OTCMarkets were mixed on Thursday, with the OTCQX US and Canada seeing slight gains.

Shares of DiaMedica Therapeutics Inc (OTCQB:DMCAF) were up more than 5% to US\$0.42 after announcing positive results from a U.S. Food and Drug Administration meeting regarding planned clinical trials for patients with chronic kidney disease. The Minneapolis-based biopharmaceutical company develops treatments for neurological and kidney diseases.

READ: First Cobalt Corp assays broad zones of mineralisation at Canadian Cobalt Camp

First Cobalt Corp (OTCQX:FTSSF) announced that recent drilling results show that the strike length has doubled to 200 meters in the Kerr area's mineralized zone. Shares of the Toronto-based company were up nearly 4% to US\$0.59.

High Hampton Holdings (OTCMKTS:HHPHF, CSE:HC) has received approval from the Coachella City Planning Commission for cannabis farming. The area was made famous by the namesake music festival, which has featured mega stars like Beyonce and Eminem. Shares were up nearly 5% to US\$0.87.

Cannabis company Choom Holdings Inc's (OTCQB:CHOOF) shares jumped nearly 3% to US\$0.71 after announcing that it had completed its acquisition of Island Green Cure Ltd, an advanced-stage cannabis production license applicant. Based in Vancouver, the company develops recreational cannabis products for sale in its retail stores.

Aequus Pharmaceuticals Inc (OTCQB:AQSZF) reported positive feedback from the FDA on its anti-nausea patch, or AQS1303. The Vancouver-based company develops treatments for neurologic and psychiatric disorders and is working to add medicinal cannabis to its portfolio. Shares were down around 2% to US\$0.22.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability,

Price: \$4.73

Market Cap: \$56.56 m

Share Information

Code: DMA

Listing: TSX-V

52 week	High	Low
	9.35	0.21

Sector: Pharma & Biotech

Website: www.diamedica.com

Company Synopsis:

DiaMedica Inc. (DiaMedica) is a biopharmaceutical company that develops therapeutic products designed for Type 1 diabetes, Type 2 diabetes treatment and certain other medically-unmet diseases.

action@proactiveinvestors.com

value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.